安脑丸联合降血压药治疗原发性高血压病的经济学评价:一项基于决策树模型的研究  

Economic evaluation of Annao Pills combined with antihypertensive drugs in treatment of primary hypertension:a study based on decision tree model

作　　者：陈子佳 崔鑫 韩晟[2] 乔萌 付常宽 王志飞[1] 谢雁鸣[1] CHEN Zi-jia;CUI Xin;HAN Sheng;QIAO Meng;FU Chang-kuan;WANG Zhi-fei;XIE Yan-ming(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;International Research Center for Medicinal Administration,Peking University,Beijing 100089,China)

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700 [2]北京大学医药管理国际研究中心,北京100089

出　　处：《中国中药杂志》2024年第6期1683-1689,共7页China Journal of Chinese Materia Medica

基　　金：国家重点研发计划项目(2018YFC1707410);科技创新工程重大攻关项目(CI2021A00702)。

摘　　要：该研究旨在评价中国医疗环境下安脑丸联合降血压药治疗原发性高血压病的经济性。从卫生体系角度出发,运用TreeAge pro 2018构建模型对2种治疗方案进行成本⁃效果分析及敏感性分析。模拟模型干预时间为2周,成本参数源于药智网,效果参数基于安脑丸加载随机对照试验(RCT)合并后的Meta分析,安脑丸组干预措施为安脑丸联合降血压药(硝苯地平控释片+氯沙坦钾片),对照组干预措施为降血压药(硝苯地平控释片+氯沙坦钾片)。基础分析显示,2组增量成本⁃效果比(ICER)为2678.67元,ICER小于2022年人均可支配收入的7.26%,即相比于单用降血压药,安脑丸联合降血压药每多治疗1例有效的原发性高血压病患者需多花费2678.67元。敏感性分析验证了基础分析结果的稳健性,概率敏感性分析显示,当患者的个人意愿支付价格高于2650元时,安脑丸组干预措施具有经济性的概率更高,与基础分析结果一致。结果表明,当个人意愿支付价格高于2650元时,原发性高血压病患者选用安脑丸联合降血压药比单用降血压药在改善有效率方面更具有经济性。The purpose of this study was to evaluate the economics of Annao Pills combined with antihypertensive drugs in the treat⁃ment of primary hypertension in the Chinese medical setting.TreeAge pro 2018 was used for cost⁃effect analysis and sensitivity analysis of the two treatment regimens.The intervention time of the simulation model was 2 weeks.The cost parameters were derived from Yaozhi.com,and the effect parameters were based on Meta⁃analysis of randomized controlled trial(RCT)involving Annao Pills.The experimental group was treated with Annao Pills combined with anti⁃hypertensive drugs(nifedipine controlled⁃release tablets+losartan potassium tablets),and the control group was treated with anti⁃hypertensive drugs(nifedipine controlled⁃release tablets+losartan po⁃tassium tablets).The basic analysis showed that the incremental cost⁃effect ratio(ICER)of the two groups was 2678.67 yuan,which was less than 7.26%of the per capita disposable income in 2022.That is,compared with anti⁃hypertensive drugs alone,Annao Pills combined with antihypertensive drugs cost 2678.67 yuan more for each additional patient with primary hypertension.The results of sensitivity analysis verified the robustness of the basic analysis results.The probability sensitivity results showed that when the patient′s personal willingness to pay the price was higher than 2650 yuan,the probability of the regimen in the experimental group was higher,which was consistent with the results of the basic analysis.In conclusion,when the price was higher than 2650 yuan,Annao Pills combined with anti⁃hypertensive drugs was more economical than anti⁃hypertensive drugs alone in terms of improving the response rate of the patients with primary hypertension.

关 键 词：安脑丸 原发性高血压病 药物经济学 成本⁃效果分析 

分 类 号：R544.11[医药卫生—心血管疾病]